Lung moistening and throat protecting composite composition based on turnip and preparation method thereof

Abstract

The invention discloses a compound composition for moistening lung and protecting throat based on turnip and a preparation method thereof. The composition comprises a turnip active component, tremella polysaccharide, modified propolis nanoparticles, fucoidan, a loquat leaf extract and a menthol-cyclodextrin inclusion compound. In the preparation process, firstly, glucosinolate in turnip is efficiently converted into active substances such as sulforaphane through glucosinase; then designing and synthesizing modified propolis nanoparticles to embed propolis flavonoids and phenolic acids, so as to improve the stability and bioavailability of the propolis flavonoids and phenolic acids; finally, all the components are integrated, and the final product is prepared through the processes of gel compounding, spray drying and the like. The raphanin content of the product reaches 9.17 mg / g, the diameters of inhibition zones on staphylococcus aureus and streptococcus pneumoniae reach 17.6 mm and 16.97 mm respectively, the inhibition rate of mouse cough reaches up to 57.14%, and the problems that a traditional product is unstable in active ingredient and single in effect are solved.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of food health care or medicine, and in particular to a lung-moistening and throat-protecting composite composition based on Brassica rapa L. and a preparation method thereof. BACKGROUND

[0002] With the universalization of air quality changes, accelerated pace of life, and overuse of the voice, the incidence of throat discomfort, dry cough, and respiratory mucosa damage has significantly increased, and the market demand for safe and effective lung-moistening and throat-protecting products is increasingly urgent. Existing products are mainly divided into three categories: first, traditional Chinese medicine compounds mainly composed of loquat leaves and monk fruit, which have unclear efficacy material basis and relatively slow effect; second, chemical synthetic components mainly composed of menthol and xylocaine, which have direct and rapid effects but may cause potential risks such as oral flora imbalance when used for a long time; and third, new biological active ingredients represented by tremella polysaccharide and fucoidan, which are still mainly added singly and lack systematic integration, and the synergistic effect cannot be fully exerted.

[0003] Brassica rapa L. is a medicinal and edible plant rich in thioglucosidase, and the enzymatic hydrolysate of thioglucosidase has significant anti-inflammatory and cell self-protection potential. The lung-moistening and throat-protecting effect of Brassica rapa L. is traditionally derived from its cough-relieving, phlegm-removing, heat-clearing, detoxifying, and tonifying effects. Compared with traditional Chinese medicine compounds, the lung-moistening and throat-protecting product based on Brassica rapa L. is more precise and stable, and compared with chemical synthetic components, it is safer and can fundamentally repair from the anti-inflammatory aspect, and compared with single new biological components, it can achieve multi-component synergy and targeted release. However, the development of Brassica rapa L. faces key bottlenecks: unclear core efficacy components, unstable active substances, low in vivo absorption and utilization rate, and insufficient technical added value of the product form which is mainly a primary processed product. SUMMARY

[0004] To solve the above problems, the present application provides a lung-moistening and throat-protecting composite composition based on Brassica rapa L. and a preparation method thereof, which solves the problems of single efficacy, unstable active ingredients, and low bioavailability of traditional lung-moistening and throat-protecting products.

[0005] The present application can be implemented by the following technical solutions: A lung-moistening and throat-protecting composite composition based on Brassica rapa L. comprises the following components by weight: 30-40 parts of Brassica rapa L. active components, 20-25 parts of tremella polysaccharide, 15-20 parts of modified bee glue nanoparticles, 8-12 parts of fucoidan, 5-8 parts of loquat leaf extract, and 3-5 parts of menthol-cyclodextrin inclusion compound.

[0006] Preferably, the preparation method of the active component of horse radish is as follows: horse radish tubers are added to a beater, broken into pulp, and then glucosinolate enzyme is added for enzymolysis. After the enzymolysis is completed, the temperature is raised to 85-90°C, and the mixture is left to stand for 10-15 min. The mixture is centrifuged at 4000-5000 rpm for 10-20 min, and the supernatant is collected. The supernatant is concentrated under reduced pressure, and then freeze-dried to obtain the active component of horse radish.

[0007] Preferably, the preparation method of the menthol-cyclodextrin inclusion compound is as follows: water and β-cyclodextrin are added to a flask, and stirred in a 50-60°C water bath. The mixture is filtered to obtain a saturated β-cyclodextrin solution. Ethanol and menthol are added to another flask, and stirred to dissolve the menthol to obtain a menthol ethanol solution. The menthol ethanol solution is added dropwise to the saturated β-cyclodextrin solution, and stirred at 50-60°C for 2-4 h. The mixture is then refrigerated for 12-24 h. The mixture is filtered, and the filter cake is washed with ice water, dried, ground, and sieved to obtain the menthol-cyclodextrin inclusion compound.

[0008] Preferably, the enzymolysis is performed at 35-45°C, pH 5.5-6.0, and a rotation speed of 100-200 rpm for 2-4 h. The amount of glucosinolate enzyme added is 0.05%-0.15% of the mass of the horse radish.

[0009] Preferably, the ratio of β-cyclodextrin to menthol is (1-1.2) g:1 g.

[0010] A preparation method of a lung-moistening and throat-protecting composite composition based on horse radish includes the following steps: Step 1: water, the active component of horse radish, and tremella polysaccharide are added to a flask, mixed uniformly, and then genipin is added. The mixture is stirred to obtain a composite gel. Step 2: propolis ethanol extract, medium-chain triglyceride, and sorbitan ester 80 are added to a flask, and stirred to dissolve to form a uniform oil phase. Deionized water is then added, and the mixture is homogenized at 8000-8500 rpm for 2-6 min to obtain a propolis emulsion. Chitosan is dissolved in a 1% acetic acid solution, and filtered. Aqueous sodium tripolyphosphate solution and the propolis emulsion are added dropwise, and stirred for 30-50 min. Aqueous sodium alginate solution is added dropwise in an ice water bath, and the mixture is stirred for another 2-3 h. Calcium chloride solution is then added to crosslink and solidify the mixture for 1-3 h. The suspension is centrifuged in a centrifuge at 15000-17000 x g at 4°C for 30-40 min. The supernatant is washed with phosphate buffer, and then resuspended with a mannitol solution. The mixture is freeze-dried for 24-36 h, and then desiccated for 12-20 h. The mixture is ground and sieved to obtain modified propolis nanoparticles with a particle size of 80-120 nm. g ​Step 3, the composite gel is fully stirred and mixed with modified propolis nanoparticles, fucoidan and loquat leaf extract, then low-temperature spray dried, and then mixed with menthol-cyclodextrin inclusion compound in a double-cone mixer to obtain a composite lung-moistening and throat-protecting composition based on brassica rapa.

[0011] Preferably, the stirring speed in step 1 is 100-300 rpm, the temperature is 25-40℃, and the time is 2-4h.

[0012] Preferably, the amount of genipin added in step 1 is 1%-3% of the mass of brassica rapa-tremella polysaccharide.

[0013] Preferably, the ratio of propolis ethanol extract, medium-chain triglyceride, sorbitan ester 80 and chitosan in step 2 is 10g: (2-3) g: (0.6-1) g: (1.5-2.5) g Preferably, the mixing speed of the double-cone mixer in step 3 is 12-15 rpm, and the mixing time is 20-40 min.

[0014] The beneficial effects of the present application are: The present application efficiently converts the glucosinolates in brassica rapa into active substances such as sulforaphane through glucosinolate enzymolysis, greatly increasing the content and biological activity of the core active ingredients. Sulforaphane has clear anti-inflammatory and cell protection effects, directly inhibiting core inflammatory pathways such as NF-κB, reducing damage to respiratory mucosa from the source, and achieving fundamental repair. Modified propolis nanoparticles act as a delivery carrier, nanoscale embedding flavonoids and phenolic acids in propolis, stable delivery of flavonoids and inhibition of inflammatory mediators, and increasing the inhibition rate of inflammatory factor IL-6 secretion. Sulforaphane and propolis flavonoids work together, the former destroys bacterial cell membranes and induces oxidative stress, and the latter inhibits bacterial nucleic acid and protein synthesis. Antibacterial tests show that the MIC value of the product for staphylococcus aureus is as low as 0.082 mg / mL, and the antibacterial circle diameter is 17.6 mm, with high antibacterial capacity. In addition, sulforaphane and propolis flavonoids reduce irritation from the root by reducing respiratory inflammation, animal tests show that the cough inhibition rate is as high as 57.14%, and the cough frequency is significantly reduced. The present application solves the problems of unstable active ingredients and low utilization rate in traditional lung-moistening and cough-relieving products, achieves synergistic effects in anti-inflammatory, antibacterial and cough-relieving three core functions, and provides a reliable technical solution for developing efficient and stable lung-moistening and throat-protecting products. BRIEF DESCRIPTION OF DRAWINGS

[0015] The accompanying drawings are included to provide a further understanding of the application, and constitute a part of the specification, illustrate the application, and are used to explain the application without limiting the application. In the drawings:

[0016] Figure 1sulforaphane and total flavonoids content of the complex composition; Figure 2 antibacterial activity of the complex composition; Figure 3 anti-inflammatory activity and cough-relieving efficacy of the complex composition. DETAILED DESCRIPTION

[0017] The following detailed description of the embodiments of the present application is given on the premise of the technical solutions of the present application, and detailed implementation manners and processes are given, but the protection scope of the present application is not limited to the following embodiments. The experimental methods not specified in the following embodiments are generally performed according to conventional conditions.

[0018] Embodiment 1 The lung-moistening and vocal-cord-protecting complex composition based on Bryonia is prepared by the following steps:

[0019] The lung-moistening and vocal-cord-protecting complex composition based on Bryonia is prepared by the following steps: Step 1, 1 kg of Bryonia tuber is added to a beater to be crushed and pulped, and then 50 g of thioglycolate is added. The enzyme is hydrolyzed at 35℃ and pH 5.5 for 2 h at a speed of 100 rpm. After the hydrolysis is completed, the temperature is raised to 85℃, and the mixture is left to stand for 10 min. The mixture is centrifuged at 4000 rpm for 20 min. The supernatant is collected, concentrated under reduced pressure, and freeze-dried to obtain the active component of Bryonia; Step 2, 300 mL of water and 2 g of β-cyclodextrin are added to a flask, stirred in a 50℃ water bath, filtered, and a saturated β-cyclodextrin solution is obtained. 8 mL of ethanol and 2 g of menthol are added to another flask, stirred and dissolved, and a menthol ethanol solution is obtained. The menthol ethanol solution is added dropwise to the saturated β-cyclodextrin solution, stirred at 50℃ for 2 h, and then refrigerated for 12 h. The filter cake is washed with ice water, dried, ground, and sieved to obtain the menthol-β-cyclodextrin inclusion compound; Step 3, 10 g of propolis ethanol extract, 2 g of medium-chain triglyceride, and 0.6 g of sorbitan ester 80 are added to a flask, stirred and dissolved at 60℃ to form a uniform oil phase. Then 50 mL of preheated deionized water is added, and the mixture is homogenized at 8000 rpm for 2 min to obtain a propolis emulsion. 1.5 g of chitosan is dissolved in 100 mL of 1% acetic acid solution, filtered, and 50 mL of a sodium tripolyphosphate aqueous solution and the above-mentioned propolis emulsion are slowly added dropwise. The mixture is stirred for 30 min, and 80 mL of a sodium alginate aqueous solution is added dropwise while stirring in an ice water bath. The stirring is continued for 2 h, and then 5 mL of 1 mol / L calcium chloride solution is added for crosslinking and solidification for 1 h. The suspension is centrifuged in a centrifuge at 4℃ at 15000× gCentrifugation for 30 min, the supernatant was washed with phosphate buffer, resuspended with mannitol solution, freeze-drying for 24h, desiccation for 12h, grinding and sieving, to obtain modified propolis nanoparticles with a particle size of 80nm; Step 4, add 400mL water, active components of brassica rapa, tremella polysaccharide to the flask, mix well, then add 1g genipin, stir at 100rpm speed, 25℃ for 4h to obtain a composite gel; Step 5, mix the composite gel with modified propolis nanoparticles, fucoidan, and extract of flos lonicerae, spray dry at low temperature, then mix with menthol-cyclodextrin inclusion complex in a double-cone mixer at 12rpm speed for 40min to obtain a composite composition for moistening the lungs and protecting the voice based on brassica rapa.

[0020] Example 2 A composite composition for moistening the lungs and protecting the voice based on brassica rapa in this example includes the following components by weight: active components of brassica rapa 40 parts, tremella polysaccharide 25 parts, modified propolis nanoparticles 20 parts, fucoidan 12 parts, extract of flos lonicerae 8 parts, and menthol-cyclodextrin inclusion complex 5 parts.

[0021] A method for preparing a composite composition for moistening the lungs and protecting the voice based on brassica rapa, including the following steps: Step 1, add 1kg of brassica rapa tuber to a beater, crush and make pulp, then add 150g of thioglycoside enzyme, and hydrolyze at 200rpm speed under the condition of 45℃ and pH 6.0 for 4h. After the hydrolysis is completed, raise the temperature to 90℃, stand for 15min, centrifuge at 5000rpm for 10min, collect the supernatant, concentrate under reduced pressure, freeze-dry to obtain active components of brassica rapa; Step 2, add 300mL of water and 2.4g of β-cyclodextrin to a flask, stir in a 60℃ water bath, filter to obtain a saturated β-cyclodextrin solution; add 8mL of ethanol and 2g of menthol to another flask, stir to dissolve, to obtain a menthol ethanol solution; add the menthol ethanol solution to the saturated β-cyclodextrin solution, stir at 60℃ for 4h, then refrigerate for 24h, filter, wash the filter cake with ice water, dry, grind and sieve to obtain a menthol-cyclodextrin inclusion complex; Step 3, add 10 g propolis ethanol extract, 3 g medium-chain triglyceride, 1 g sorbitan ester 80 into a flask, stir to dissolve at 70℃ to form a uniform oil phase, then add 50 mL preheated deionized water, homogenize at 8500 rpm for 6 min to prepare a propolis emulsion; dissolve 2.5 g chitosan in 100 mL 1% acetic acid solution, filter, slowly add 50 mL aqueous sodium tripolyphosphate solution and the above propolis emulsion, stir for 50 min, add 80 mL aqueous sodium alginate solution dropwise while stirring in an ice water bath, continue stirring for 3 h, then add 5 mL 1 mol / L calcium chloride solution, crosslink and solidify for 3 h, centrifuge the suspension in a centrifuge at 4℃ for 40 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 36 h, desiccate for 20 h, grind and sieve to obtain modified propolis nanoparticles with a particle size of 120 nm; g Step 3, add 10 g propolis ethanol extract, 3 g medium-chain triglyceride, 1 g sorbitan ester 80 into a flask, stir to dissolve at 70℃ to form a uniform oil phase, then add 50 mL preheated deionized water, homogenize at 8500 rpm for 6 min to prepare a propolis emulsion; dissolve 2.5 g chitosan in 100 mL 1% acetic acid solution, filter, slowly add 50 mL aqueous sodium tripolyphosphate solution and the above propolis emulsion, stir for 50 min, add 80 mL aqueous sodium alginate solution dropwise while stirring in an ice water bath, continue stirring for 3 h, then add 5 mL 1 mol / L calcium chloride solution, crosslink and solidify for 3 h, centrifuge the suspension in a centrifuge at 4℃ for 40 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 36 h, desiccate for 20 h, grind and sieve to obtain modified propolis nanoparticles with a particle size of 120 nm; Step 4, add 400 mL water, active component of brassica rapa, tremella polysaccharide into a flask, mix well, then add 3 g genipin, stir at a speed of 300 rpm at 40℃ for 2 h to obtain a composite gel; Step 5, mix the composite gel with modified propolis nanoparticles, fucoidan, and extract of flos lonicerae, spray dry at low temperature, then mix with menthol-cyclodextrin inclusion compound in a double-cone mixer at a speed of 15 rpm for 20 min to obtain a brassica rapa-based lung-moistening and throat-protecting composite composition.

[0022] Example 3 A brassica rapa-based lung-moistening and throat-protecting composite composition in this example comprises the following components by weight: active component of brassica rapa 35 parts, tremella polysaccharide 20 parts, modified propolis nanoparticles 15 parts, fucoidan 10 parts, extract of flos lonicerae 8 parts, and menthol-cyclodextrin inclusion compound 4 parts.

[0023] A method for preparing a brassica rapa-based lung-moistening and throat-protecting composite composition, comprising the following steps: Step 1, add 1 kg of brassica rapa tuber to a beater, crush and pulp, then add 100 g of thioglycoside enzyme, and enzymatically hydrolyze at 40℃ and pH 6.0 at a speed of 150 rpm for 3 h. After the enzymatic hydrolysis is completed, increase the temperature to 90℃, stand for 10 min, and centrifuge at 4500 rpm for 15 min. Collect the supernatant, concentrate under reduced pressure, and freeze-dry to obtain the active component of brassica rapa; Step 2, add 300 mL water and 2.2 g β-cyclodextrin into a flask, stir in a 55°C water bath, filter, and prepare a β-cyclodextrin saturated solution; add 8 mL ethanol and 2 g menthol into another flask, stir and dissolve, and prepare a menthol ethanol solution; drop the menthol ethanol solution into the β-cyclodextrin saturated solution, stir and react at 55°C for 3 h, then refrigerate for 18 h, filter, wash the filter cake with ice water, dry, grind, and sieve to obtain a menthol-cyclodextrin inclusion compound; Step 3, add 10 g propolis ethanol extract, 2 g medium-chain triglyceride, and 0.8 g sorbitan ester 80 into a flask, stir and dissolve at 65°C to form a uniform oil phase, then add 50 mL preheated deionized water, and homogenize at 8500 rpm for 4 min to prepare a propolis emulsion; dissolve 2 g chitosan in 100 mL 1% acetic acid solution, filter, slowly drop 50 mL sodium tripolyphosphate aqueous solution and the above propolis emulsion, stir for 40 min, drop 80 mL sodium alginate aqueous solution in an ice water bath while stirring, continue to stir for 2.5 h, then add 5 mL 1 mol / L calcium chloride solution to crosslink and solidify for 2 h, centrifuge the suspension in a centrifuge at 17000 x g at 4°C for 35 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 30 h, desiccate for 16 h, grind, and sieve to obtain modified propolis nanoparticles with a particle size of 100 nm; g Step 3, add 10 g propolis ethanol extract, 2 g medium-chain triglyceride, and 0.8 g sorbitan ester 80 into a flask, stir and dissolve at 65°C to form a uniform oil phase, then add 50 mL preheated deionized water, and homogenize at 8500 rpm for 4 min to prepare a propolis emulsion; dissolve 2 g chitosan in 100 mL 1% acetic acid solution, filter, slowly drop 50 mL sodium tripolyphosphate aqueous solution and the above propolis emulsion, stir for 40 min, drop 80 mL sodium alginate aqueous solution in an ice water bath while stirring, continue to stir for 2.5 h, then add 5 mL 1 mol / L calcium chloride solution to crosslink and solidify for 2 h, centrifuge the suspension in a centrifuge at 17000 x g at 4°C for 35 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 30 h, desiccate for 16 h, grind, and sieve to obtain modified propolis nanoparticles with a particle size of 100 nm; Step 4, add 400 mL water, active components of Nostoc commune, and tremella polysaccharide into a flask, mix well, then add 2 g genipin, stir at a speed of 200 rpm at 30°C for 3 h, and obtain a composite gel; Step 5, mix the composite gel with modified propolis nanoparticles, fucoidan, and extract of flos lonicerae, spray dry at low temperature, then mix with menthol-cyclodextrin inclusion compound in a double-cone mixer at a speed of 12 rpm for 30 min, and obtain a Nostoc commune-based lung-moistening and throat-protecting composite composition.

[0024] Example 4 A Nostoc commune-based lung-moistening and throat-protecting composite composition in this example comprises the following components by weight: active components of Nostoc commune 30 parts, tremella polysaccharide 25 parts, modified propolis nanoparticles 20 parts, fucoidan 12 parts, extract of flos lonicerae 5 parts, and menthol-cyclodextrin inclusion compound 3 parts.

[0025] A method for preparing a Nostoc commune-based lung-moistening and throat-protecting composite composition, comprising the following steps: Step 1: Add 1 kg of turnip tubers to a pulper, crush and pulp them, then add 150 g of glucosidase, and enzymatically hydrolyze them at 100 rpm for 4 hours at 45℃ and pH 5.5. After enzymatic hydrolysis, raise the temperature to 90℃, let stand for 10 min, centrifuge at 5000 rpm for 20 min, collect the supernatant, concentrate under reduced pressure, and freeze dry to obtain the active components of turnips. Step 2: Add 300 mL of water and 2.4 g of β-cyclodextrin to a flask, stir in a 50 °C water bath, filter to obtain a saturated β-cyclodextrin solution; add 8 mL of ethanol and 2 g of menthol to another flask, stir to dissolve, and obtain a menthol ethanol solution; add the menthol ethanol solution dropwise to the saturated β-cyclodextrin solution, stir and react at 60 °C for 2 h, then refrigerate for 24 h, filter, wash the filter cake with ice water, dry, grind and sieve to obtain the menthol-cyclodextrin inclusion complex; Step 3: Add 10g of propolis ethanol extract, 3g of medium-chain triglycerides, and 0.6g of sorbitol 80 to a flask. Stir at 70℃ to dissolve and form a homogeneous oil phase. Then add 50mL of preheated deionized water and homogenize at 8000rpm for 6min to obtain a propolis emulsion. Dissolve 2.5g of chitosan in 100mL of 1% acetic acid solution, filter, and slowly add 50mL of sodium tripolyphosphate aqueous solution and the above propolis emulsion. Stir for 50min, and then add 80mL of sodium alginate aqueous solution dropwise while stirring in an ice-water bath. Continue stirring for 2h, then add 5mL of 1mol / L calcium chloride solution for cross-linking and solidification for 3h. Centrifuge the suspension at 4℃ at 17000× g Centrifuge for 30 min, wash the supernatant with phosphate buffer, resuspend in mannitol solution, freeze dry for 24 h, desorb and dry for 20 h, grind and sieve to obtain modified propolis nanoparticles with a particle size of 120 nm. Step 4: Add 400mL of water, turnip active component, and tremella polysaccharide to the flask, mix well, then add 3g of genipin, stir at 100rpm and 25℃ for 3h to obtain composite gel. Step 5: Thoroughly mix the composite gel with modified propolis nanoparticles, fucoidan, and loquat leaf extract, spray dry at low temperature, and then mix with menthol-cyclodextrin inclusion complex in a double cone mixer at 15 rpm for 40 min to obtain a lung-moistening and throat-protecting composite composition based on turnip.

[0026] Comparative Example 1: The difference between this comparative example and Example 1 is that no modified propolis nanoparticles are added.

[0027] This comparative example presents a lung-moistening and throat-protecting compound composition based on turnips, comprising the following components by weight: 30 parts of turnip active components, 20 parts of tremella polysaccharide, 8 parts of fucoidan, 5 parts of loquat leaf extract, and 3 parts of menthol-cyclodextrin inclusion complex.

[0028] A preparation method of a lung-moistening and throat-protecting composite composition based on horse radish, comprising the following steps: Step 1, add 1 kg of horse radish tuber to a beater, crush and make pulp, then add 50 g of thioglycoside enzyme, and carry out enzymolysis at 35℃ and pH 5.5 and a rotating speed of 100 rpm for 2 h, after the enzymolysis, raise the temperature to 85℃, stand for 10 min, centrifuge at 4000 rpm for 20 min, collect the supernatant, concentrate under reduced pressure, and freeze-dry to obtain horse radish active component; Step 2, add 300 mL of water and 2 g of β-cyclodextrin to a flask, stir in a 50℃ water bath, filter to obtain a saturated β-cyclodextrin solution; add 8 mL of ethanol and 2 g of menthol to another flask, stir and dissolve to obtain a menthol ethanol solution; add the menthol ethanol solution to the saturated β-cyclodextrin solution dropwise, stir at 50℃ for 2 h, then refrigerate for 12 h, filter, wash the filter cake with ice water, dry, grind and sieve to obtain a menthol-β-cyclodextrin inclusion compound; Step 3, add 400 mL of water, the horse radish active component and tremella polysaccharide to a flask, mix uniformly, then add 1 g of genipin, stir at a rotating speed of 100 rpm and at 25℃ for 4 h to obtain a composite gel; Step 4, mix the composite gel, fucoidan and loquat leaf extract thoroughly, spray dry at low temperature, then mix the menthol-β-cyclodextrin inclusion compound in a double-cone mixer at a rotating speed of 12 rpm for 40 min to obtain a lung-moistening and throat-protecting composite composition based on horse radish.

[0029] Comparative Example 2: The difference between this comparative example and Example 1 is that no enzymolysis is performed, and the horse radish active component is extracted by traditional water extraction.

[0030] The lung-moistening and throat-protecting composite composition based on horse radish in the comparative example comprises the following components by weight: 30 parts of horse radish active component, 20 parts of tremella polysaccharide, 15 parts of modified propolis nanoparticles, 8 parts of fucoidan, 5 parts of loquat leaf extract, and 3 parts of menthol-β-cyclodextrin inclusion compound.

[0031] A preparation method of a lung-moistening and throat-protecting composite composition based on horse radish, comprising the following steps: Step 1, add 1 kg of horse radish tuber and 2.5 L of water to a beater, and reflux the slurry at 90℃ for 2 h, centrifuge the extract at 5000 rpm for 20 min, collect the supernatant, concentrate under reduced pressure at 60℃, and freeze-dry to obtain horse radish active component; Step 2, add 300 mL water and 2 g β-cyclodextrin into a flask, stir in a 50℃ water bath, filter to obtain a saturated β-cyclodextrin solution; add 8 mL ethanol and 2 g menthol into another flask, stir to dissolve to obtain a menthol ethanol solution; drop the menthol ethanol solution into the saturated β-cyclodextrin solution, stir at 50℃ for 2 h, then refrigerate for 12 h, filter, wash the filter cake with ice water, dry, grind and sieve to obtain a menthol-β-cyclodextrin inclusion compound; Step 3, add 10 g propolis ethanol extract, 2 g medium-chain triglyceride and 0.6 g sorbitan ester 80 into a flask, stir to dissolve at 60℃ to form a uniform oil phase, then add 50 mL preheated deionized water, homogenize at 8000 rpm for 2 min to obtain a propolis emulsion; dissolve 1.5 g chitosan in 100 mL 1% acetic acid solution, filter, slowly drop 50 mL aqueous sodium tripolyphosphate solution and the above propolis emulsion, stir for 30 min, drop 80 mL aqueous sodium alginate solution in an ice water bath while stirring, continue to stir for 2 h, then add 5 mL 1 mol / L calcium chloride solution to crosslink and solidify for 1 h, centrifuge the suspension in a centrifuge at 15000 x g at 4℃ for 30 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 24 h, resolve and dry for 12 h, grind and sieve to obtain modified propolis nanoparticles with a particle size of 80 nm; g Step 3, add 10 g propolis ethanol extract, 2 g medium-chain triglyceride and 0.6 g sorbitan ester 80 into a flask, stir to dissolve at 60℃ to form a uniform oil phase, then add 50 mL preheated deionized water, homogenize at 8000 rpm for 2 min to obtain a propolis emulsion; dissolve 1.5 g chitosan in 100 mL 1% acetic acid solution, filter, slowly drop 50 mL aqueous sodium tripolyphosphate solution and the above propolis emulsion, stir for 30 min, drop 80 mL aqueous sodium alginate solution in an ice water bath while stirring, continue to stir for 2 h, then add 5 mL 1 mol / L calcium chloride solution to crosslink and solidify for 1 h, centrifuge the suspension in a centrifuge at 15000 x g at 4℃ for 30 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 24 h, resolve and dry for 12 h, grind and sieve to obtain modified propolis nanoparticles with a particle size of 80 nm; Step 4, add 400 mL water, active components of b. nivalis and tremella polysaccharide into a flask, mix well, then add 1 g genipin, stir at a speed of 100 rpm at 25℃ for 4 h to obtain a composite gel; Step 5, mix the composite gel with modified propolis nanoparticles, fucoidan and extract of flos lonicerae, spray dry at low temperature, then mix with menthol-β-cyclodextrin inclusion compound in a double-cone mixer at a speed of 12 rpm for 40 min to obtain a lung-soothing and throat-protecting composite composition based on b. nivalis.

[0032] Comparative Example 3: The difference between this comparative example and Example 1 is that the active components of b. nivalis are replaced with extract of sargassum.

[0033] A lung-soothing and throat-protecting composite composition in this comparative example comprises the following components by weight: 30 parts of extract of sargassum, 20 parts of tremella polysaccharide, 15 parts of modified propolis nanoparticles, 8 parts of fucoidan, 5 parts of extract of flos lonicerae and 3 parts of menthol-β-cyclodextrin inclusion compound.

[0034] A method for preparing a lung-soothing and throat-protecting composite composition, comprising the following steps: Step 1, add 300 mL water and 2 g β-cyclodextrin into a flask, stir in a 50°C water bath, filter, and prepare a β-cyclodextrin saturated solution; add 8 mL ethanol and 2 g menthol into another flask, stir and dissolve, and prepare a menthol ethanol solution; drop the menthol ethanol solution into the β-cyclodextrin saturated solution, stir and react at 50°C for 2 h, then refrigerate for 12 h, filter, wash the filter cake with ice water, dry, grind, and sieve to obtain a menthol-cyclodextrin inclusion compound; Step 2, add 10 g propolis ethanol extract, 2 g medium-chain triglyceride, and 0.6 g sorbitan ester 80 into a flask, stir and dissolve at 60°C to form a uniform oil phase, then add 50 mL preheated deionized water, and homogenize at 8000 rpm for 2 min to prepare a propolis emulsion; dissolve 1.5 g chitosan in 100 mL 1% acetic acid solution, filter, slowly drop 50 mL sodium tripolyphosphate aqueous solution and the above propolis emulsion, stir for 30 min, drop 80 mL sodium alginate aqueous solution in an ice water bath while stirring, continue to stir for 2 h, then add 5 mL 1 mol / L calcium chloride solution to crosslink and solidify for 1 h, centrifuge the suspension in a centrifuge at 4°C at 15000 x g for 30 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 24 h, desolvate for 12 h, grind, and sieve to obtain modified propolis nanoparticles with a particle size of 80 nm; g Step 2, add 10 g propolis ethanol extract, 2 g medium-chain triglyceride, and 0.6 g sorbitan ester 80 into a flask, stir and dissolve at 60°C to form a uniform oil phase, then add 50 mL preheated deionized water, and homogenize at 8000 rpm for 2 min to prepare a propolis emulsion; dissolve 1.5 g chitosan in 100 mL 1% acetic acid solution, filter, slowly drop 50 mL sodium tripolyphosphate aqueous solution and the above propolis emulsion, stir for 30 min, drop 80 mL sodium alginate aqueous solution in an ice water bath while stirring, continue to stir for 2 h, then add 5 mL 1 mol / L calcium chloride solution to crosslink and solidify for 1 h, centrifuge the suspension in a centrifuge at 4°C at 15000 x g for 30 min, wash the supernatant with phosphate buffer, resuspend with a mannitol solution, freeze-dry for 24 h, desolvate for 12 h, grind, and sieve to obtain modified propolis nanoparticles with a particle size of 80 nm; Step 3, add 400 mL water, fathead extract, and tremella polysaccharide into a flask, mix well, then add 1 g genipin, stir at a speed of 100 rpm at 25°C for 4 h, and obtain a composite gel; Step 4, mix the composite gel, modified propolis nanoparticles, fucoidan, and loquat leaf extract well, spray dry at low temperature, then mix with the menthol-cyclodextrin inclusion compound in a double-cone mixer at a speed of 12 rpm for 40 min, and obtain a lung-moistening and throat-protecting composite composition.

[0035] Performance test 1 Test of sulforaphane and total flavonoid content (1) Sulforaphane content: sulforaphane standard was weighed, dissolved with methanol, and prepared into 1, 5, 10, 20, 50 μg / mL standard working solution. 0.1 g of the compound composition sample was weighed and placed in a 10 mL centrifuge tube, 5 mL of 70% methanol aqueous solution (v / v) was added, vortexed and mixed, placed in an ultrasonic extractor, extracted at 40°C for 30 min, the supernatant was taken, filtered with a 0.22 μm microporous filter, and the filtrate was transferred to a sample vial. The standard working solution of different concentrations was injected in turn, and the standard curve was drawn with the peak area as the vertical coordinate and the standard concentration as the horizontal coordinate. The sample solution was injected after treatment, and the sulforaphane content in the sample solution was calculated according to the peak area and the standard curve regression equation. Sulforaphane content (mg / g) = (C x V x N) / M. Wherein C is the sample solution concentration (μg / mL) calculated from the standard curve, V is the sample constant volume (mL), N is the dilution multiple, and M is the mass of the sample (g).

[0036] (2) Total flavone content: 10 mg of rutin standard was dried to constant weight, dissolved with 60% ethanol and constant volume to a 100 mL volumetric flask to obtain a rutin standard stock solution with a concentration of 0.1 mg / mL. Take 6 10 mL stoppered colorimetric tubes, according to Table 1, add 0.3 mL of 5% sodium nitrite solution to each tube, shake well, stand for 6 min, add 0.3 mL of 10% aluminum nitrate solution, shake well, stand for 6 min, add 4 mL of 4% sodium hydroxide solution, constant volume to the mark with 60% ethanol, shake well, stand for 15 min. At 510 nm wavelength, zero with the blank tube, measure the absorbance of each tube, take the rutin content as the horizontal coordinate and the absorbance as the vertical coordinate, draw the standard curve, and obtain the regression equation. 0.1 g of the compound composition sample was weighed, dissolved with 60% ethanol, transferred and constant volume to a 50 mL volumetric flask. 1 mL of the sample solution was taken in a 10 mL stoppered colorimetric tube, 1 mL of 60% ethanol was added, and the subsequent color development operation was exactly the same as that for drawing the standard curve. The reagent blank was zeroed, and the absorbance of the sample solution was measured at 510 nm wavelength. The sample absorbance was substituted into the regression equation of the rutin standard curve to calculate the rutin content in the sample test solution. Total flavone content (mg / g, calculated as rutin) = (X x V 总 ) / (V 测 x M x 1000), wherein X is the rutin amount (μg) of the sample test solution calculated from the standard curve, V 总 is the total sample constant volume (50 mL), V 测 is the sample volume (1 mL) taken for testing, M is the mass of the sample (g), and 1000 is the unit conversion coefficient.

[0037] Table 1

[0038] The retention rate of sulforaphane and total flavonoids was determined after 6 months of storage at 40°C and 75% relative humidity, according to the same test method.

[0039] The regression equation obtained from the absorbance of the standard working solution is as follows: Sulforaphane y = 35482x + 1254 (R 2 = 0.9998) Total flavonoids y = 0.0045x + 0.021 (R 2 = 0.9995) Table 2 Sulforaphane and total flavonoid content test data

[0040] As can be seen from Table 2, Examples 1-4 maximized the conversion of glucosinolate in Brassica rapa to isothiocyanates such as sulforaphane by catalysis of thioglucosidase. The modified propolis nanoparticles provided a high-surface-area carrier to embed small-molecule flavonoids and phenolic acids. Ultimately, the content and storage stability of sulforaphane (8.55-9.17 mg / g) and flavonoids (85.24-89.71 mg / g) were superior to those of the comparative examples. In contrast, Comparative Example 1 did not add modified propolis nanoparticles, and the unembedded flavonoids were extremely susceptible to degradation, resulting in poor stability and a very low total flavonoid content (15.89 mg / g) in the composite composition, with no total flavonoids detected after 6 months. Comparative Example 2 used traditional water extraction to extract active components from Brassica rapa, which could not effectively convert glucosinolate, and the converted components were unstable, resulting in a very low sulforaphane retention rate (58.3%) in the composite composition, indicating that glucosinolate hydrolysis is key to increasing the content and stability of sulforaphane. Comparative Example 3 used a Helicteres angustifolia extract to replace the active components of Brassica rapa, which did not contain sulforaphane, resulting in no sulforaphane content being detected.

[0041] 2 In vitro antibacterial activity (1) Inhibition zone diameter: Mueller-Hinton agar medium and broth medium were used to activate Staphylococcus aureus and Streptococcus pneumoniae to the logarithmic growth phase. An equal amount of composite composition sample was weighed in triplicate, and a 100 ng / mL stock solution was prepared using phosphate buffer at pH 6.8 and phosphate buffer at pH 5.5 to simulate the oral environment and simulate the inflamed throat environment, respectively. The two groups of stock solutions were incubated in a 37°C constant temperature shaker at 100 rpm for 1 h, and the two groups of sample solutions were serially diluted with the corresponding pH buffer to obtain the test gradient concentration solutions, and sterile buffer and gentamicin solution were set as negative and positive controls, respectively. 100 μL of each concentration solution was added to the center of the Mueller-Hinton agar medium, and the medium was incubated at 37°C for 18 h to observe the inhibition zone diameter. 8A bacterial suspension of CFU / mL was evenly spread on MH agar plates. Sterile Oxford cups were placed at equal intervals on the plates, and 200 μL of each concentration of sample solution, negative control solution, and positive control solution pretreated at different pH values ​​was added to each well. The plates were incubated at 4°C for 2 hours, then transferred to a 37°C incubator for 18–24 hours. The diameter of each inhibition zone was accurately measured. Each sample was tested in triplicate, and the average value was taken.

[0042] (2) Minimum Inhibition Concentration (MIC): The activated bacterial culture was adjusted to 0.5 McFarland turbidity standard (approximately 1×10⁻⁶) using MH broth. 8 (CFU / mL), then diluted 100 times with broth to obtain approximately 1×10⁻⁶ CFU / mL. 6 Working bacterial suspension at CFU / mL. In a 96-well cell culture plate, add 100 μL of MH broth to each well. Add 100 μL of pH-pretreated sample stock solution to the first row of wells, mix well, and then add 100 μL to the second row of wells. Serial dilutions are performed to the desired concentration gradient, with 100 μL of working bacterial suspension added to each well afterward. Set up a bacterial growth control (broth + bacterial suspension), a negative control (broth + sample stock solution), and a blank control (broth only). Seal the 96-well plate and incubate at 37°C for 18-24 hours. Visually observe the sample concentration; the lowest concentration that completely inhibits bacterial growth (clear wells) is defined as the MIC (micronizable concentration) at the corresponding pH. A lower MIC indicates stronger antibacterial activity.

[0043] Table 3. In vitro antibacterial activity test data.

[0044] As shown in Table 3, all examples exhibited inhibition zones greater than 16.84 mm against Staphylococcus aureus and greater than 14.28 mm against Streptococcus pneumoniae. The growth of both bacteria was inhibited at concentrations of 0.082 mg / mL and 0.391 mg / mL, respectively, demonstrating higher antibacterial efficiency. This is mainly because: sulforaphane in the active component of turnip can penetrate the cell membrane, disrupt its structure, leading to leakage of contents, inhibiting bacterial metabolic enzymes, interfering with energy metabolism, promoting the accumulation of reactive oxygen species within bacteria, causing oxidative damage, and ultimately leading to bacterial death; flavonoids in propolis extract can bind to peptidoglycan in the bacterial cell wall, disrupting structural integrity and inhibiting bacterial nucleic acid and protein synthesis. In contrast, Comparative Example 1 lacked flavonoids in the modified propolis extract, resulting in a weak antibacterial substance base and a MIC > 50 against Streptococcus pneumoniae, significantly reducing its antibacterial effect. Comparative Example 2 did not undergo enzymatic hydrolysis, so glucosinolates could not be efficiently converted into active substances such as sulforaphane, limiting its antibacterial strength. Comparative Example 3 used Malva nut extract, which does not contain sulforaphane and cannot destroy bacterial cell membranes, inhibit bacterial metabolic enzymes, or induce bacterial oxidative stress, thus its antibacterial effect is inferior to that of turnip hydrolysate.

[0045] 3Cell level anti-inflammatory activity Step 1, human immortalized laryngeal epithelial cells (Hep-2 cells) were resuscitated and routinely cultured using DMEM medium containing 10% fetal bovine serum and 1% double antibody. When the cells grew to the logarithmic phase, they were inoculated into a 96-well cell culture plate at a density of 5 x 10 4 cells per well, and 100 μL of complete culture medium was added to each well. The culture plate was incubated in a 37°C, 5% CO2 incubator for 24 h.

[0046] Step 2, the cells were randomly divided into four groups: (1) blank control group: complete culture medium without lipopolysaccharide (LPS) and sample; (2) LPS model group: complete culture medium containing only LPS stimulant; (3) positive control group: complete culture medium containing LPS and 1 μM dexamethasone; (4) sample group: multiple concentration gradients (0.1, 0.5, 1.0 mg / mL) were set. Except for the blank group, the sample group and the positive control group were first replaced with culture medium containing the corresponding concentration of the test substance and incubated in the incubator for 2 h.

[0047] Step 3, LPS solution was added to each well of the LPS model group, the positive control group, and each sample group, with a final stimulation concentration of 1 μg / mL in the well. Continue to incubate in the incubator for 24 h. Collect the cell supernatant and transfer it to a centrifuge tube. Centrifuge at 4°C, 3000 rpm for 10 min, collect the supernatant, aliquot and store at -80°C.

[0048] Step 4, follow the instructions for the human pro-inflammatory factor interleukin-6 (IL-6) detection kit. The instructions are as follows: add the standard and the sample to be tested in the pre-coated antibody enzyme-labeled plate in turn, incubate and wash, then add the biotinylated detection antibody, incubate and wash again, add horseradish peroxidase-labeled streptavidin, incubate and wash, then add the substrate TMB solution for color development reaction, and finally add the stop solution to stop the reaction. Immediately use the enzyme-labeled instrument to measure the OD 450 , according to the concentration and OD value of the standard, draw a standard curve, and calculate the concentration of IL-6 in each sample well (C 样品 ). Calculate the inhibition rate of inflammatory factors.

[0049] Inhibition rate (%) = [1 - (C 样品 / C 模型 )] x 100%, where Cmodel is the average concentration of cytokines in the LPS model group.

[0050] Table 4 Cell level anti-inflammatory activity test data table (sample concentration 100 μg / mL)

[0051] As can be seen from Table 4, the IL-6 secretion inhibition rate of all examples is as high as 79.9%, which is due to the direct inhibition of the NF-κB core inflammatory pathway by the glucosinolate enzymolysis product sulforaphane, and the stable delivery of the anti-inflammatory medium by the propolis flavone through the nano carrier. In contrast, the inhibition rate of Comparative Example 1 is only 42.6%, which is significantly lower than that of Example 1, because Comparative Example 1 lacks flavonoid anti-inflammatory substances and modified propolis nanoparticle carriers. Comparative Example 2 is not subjected to enzymolysis, and the glucosinolate cannot be effectively converted into isothiocyanate anti-inflammatory substances, so the content of sulforaphane is extremely low, resulting in an IL-6 secretion inhibition rate of 51.4% for the prepared product.

[0052] 4Animal model cough and phlegm relief efficacy Take several healthy mice with a body weight of 18-22 g, half male and half female. Randomly divide them into the following 5 groups according to body weight, no less than 10 mice in each group: blank control group, model control group, positive drug control group (such as giving Jizhi Syrup), test sample group. Each group is given intragastrical administration at a volume of 0.1 mL / 10 g of body weight, and the blank control group and the model control group are given the same volume of normal saline, once a day, for 5-7 days of continuous administration. 1 h after this administration, the mice in each group are placed in a 500 mL glass bell jar with transparent bottom and filter paper at the bottom. A spray device is used to uniformly spray 0.3 mL of concentrated ammonia water (25%-28%) into the bell jar through a conduit, and the spraying time is controlled within 3 s. Timing is started immediately and observation is carried out. The time from the start of ammonia water spraying to the first abdominal muscle contraction, mouth opening, and short and loud sound of each mouse is recorded as one cough. The total number of coughs of each mouse within 3 min is recorded. The cough inhibition rate (%) = [(average cough frequency of the model control group - average cough rate of the administration group) / average cough frequency of the model control group] x 100%.

[0053] Table 5 Animal model cough and phlegm relief efficacy test data table

[0054] As can be seen from Table 5, all examples exhibit strong cough-relieving activity, with a cough inhibition rate as high as 57.14%, which is directly attributed to the anti-inflammatory and nerve-regulating effects of sulforaphane produced by enzymolysis of Brassica rapa L., which can reduce respiratory tract irritation from the source, and the cough and phlegm relief efficacy of loquat extract combined with the anti-inflammatory effects of the active components of Brassica rapa L. and propolis nanoparticles, forming a comprehensive cough-relieving mechanism in multiple directions. Compared with Example 1, Comparative Example 1 lacks propolis nanoparticles, and the cough inhibition rate of the prepared composition is only 28.57%, which is not good for cough relief. Comparative Examples 2 and 3 both lack the active components of Brassica rapa L., and the content of sulforaphane and other highly effective anti-inflammatory components in the prepared composite is low, resulting in poor cough and phlegm relief effects.

[0055] The above merely describes preferred specific embodiments of the present application, but the protection scope of the present application is not limited thereto, and any person skilled in the art, according to the technical solution and inventive concept of the present application, makes equivalent replacement or change within the technical range disclosed by the present application, which should be covered within the protection scope of the present application.

Claims

1. A lung-soothing and voice-protecting composite composition based on a horse radish, characterized in that, The composition comprises the following components by weight: 30-40 parts of active component of scorzonera hispanica, 20-25 parts of tremella polysaccharide, 15-20 parts of modified propolis nanoparticles, 8-12 parts of fucoidan, 5-8 parts of extract of leaf of eriobotrya japonica, and 3-5 parts of menthol-cyclodextrin inclusion compound.

2. The Eruca sativa based larynx soothing composite composition as claimed in claim 1, wherein, The preparation method of the active component of scorzonera hispanica is as follows: scorzonera hispanica tuber is added into a beater, crushed and pulped, then thioglycosidase is added for enzymolysis, after the enzymolysis is completed, the temperature is raised to 85-90℃, and the mixture is statically placed for 10-15 min, then centrifuged at 4000-5000 rpm for 10-20 min, the supernatant is collected, concentrated under reduced pressure, freeze-dried, and the active component of scorzonera hispanica is obtained.

3. The Eruca sativa based larynx soothing composite composition as claimed in claim 1, wherein, The preparation method of the menthol-cyclodextrin inclusion compound is as follows: water and β-cyclodextrin are added into a flask, stirred in a 50-60℃ water bath, filtered, and a saturated β-cyclodextrin solution is prepared; ethanol and menthol are added into another flask, stirred and dissolved, and a menthol ethanol solution is prepared; the menthol ethanol solution is added dropwise into the saturated β-cyclodextrin solution, stirred and reacted at 50-60℃ for 2-4 h, then refrigerated for 12-24 h, suction filtered, the filter cake is washed with ice water, dried, ground and sieved, and the menthol-cyclodextrin inclusion compound is obtained.

4. The Eruca sativa based larynx soothing composite composition as claimed in claim 2, wherein, The enzymolysis conditions are as follows: the enzymolysis is carried out at 35-45℃ and pH 5.5-6.0 for 2-4 h at a rotation speed of 100-200 rpm, and the addition amount of thioglycosidase is 0.05%-0.15% of the mass of scorzonera hispanica.

5. The Eruca sativa based larynx soothing and lung moisturizing composite composition as claimed in claim 3, wherein, The ratio of β-cyclodextrin to menthol is (1-1.2) g:1 g.

6. The Eruca sativa based larynx soothing composite composition as claimed in claim 1, wherein, The preparation method of the lung-moistening and throat-protecting composite composition based on scorzonera hispanica comprises the following steps: Step 1: water, the active component of scorzonera hispanica, and tremella polysaccharide are added into a flask, mixed uniformly, then geniposide is added, stirred and reacted, and a composite gel is obtained; Step 2: propolis ethanol extract, medium-chain triglyceride, and sorbitan ester 80 are added into a flask, stirred and dissolved at 60-70℃ to form a uniform oil phase, then preheated deionized water is added, homogenized at 8000-8500 rpm for 2-6 min to prepare a propolis emulsion; chitosan is dissolved in 1% acetic acid solution, filtered, and an aqueous sodium tripolyphosphate solution and the propolis emulsion are added dropwise, stirred for 30-50 min, an aqueous sodium alginate solution is added dropwise in an ice water bath, continuously stirred for 2-3 h, then a calcium chloride solution is added for crosslinking and solidification for 1-3 h, the suspension is centrifuged in a centrifuge at 4℃ at 15000-17000×g for 30-40 min, the supernatant is washed with a phosphate buffer solution, then resuspended with a mannitol solution, freeze-dried for 24-36 h, desolvated and dried for 12-20 h, ground and sieved, and modified propolis nanoparticles with a particle size of 80-120 nm are obtained; Step 3: the composite gel, modified propolis nanoparticles, fucoidan, and extract of leaf of eriobotrya japonica are fully stirred and mixed, low-temperature spray dried, then mixed uniformly with the menthol-cyclodextrin inclusion compound in a double-cone mixer, and the lung-moistening and throat-protecting composite composition based on scorzonera hispanica is obtained.

7. A method of preparing the Raphanus sativus based lung and vocal cord soothing composite composition according to claim 6, characterized by, In step 1, the stirring reaction is carried out at a rotation speed of 100-300 rpm, a temperature of 25-40℃, and for 2-4 h.

8. A method of preparing the Raphanus sativus based lung and vocal cord soothing composite composition according to claim 6, characterized by, The added amount of genipin in step 1 is 1%-3% of the mass of the Bryonia coelestis-Tremella polysaccharide.

9. A method of preparing the Raphanus sativus based lung and vocal cord soothing composite composition according to claim 6, characterized by, The ratio of the propolis ethanol extract, medium-chain triglyceride, sorbitan ester 80 and chitosan in step 2 is 10g:(2-3)g:(0.6-1)g:(1.5-2.5)g.

10. A method of preparing the Raphanus sativus based lung and vocal cord soothing composite composition according to claim 6, characterized in that, The mixing speed of the double-cone mixer in step 3 is 12-15rpm, and the mixing time is 20-40min.

Images